tirzepatide patient education pdf Taking back control: The experience of adults using semaglutide and for obesity treatment - A qualitative study Frontiers | Tirzepatide's innovative applications

Cardiovascular benefits include significant reductions in systolic and diastolic blood pressure (mean systolic reduction of 9.9 mm Hg in non-diabetic adults and 6.5 mm Hg in those with diabetes), improved lipid profiles, and lower C-reactive protein levels, all of which are relevant for cardiovascular risk reduction

Lillys triple agonist retatrutide delivered weight loss of an average of 28.7% in TRIUMPH-4

Not surprisingly, #GLP-1 agonists dont work as well in the real world as they do in clinical trials

Shift of focus Given the scale of the obesity problem and the substantial healthcare costs associated with the widespread implementation of GLP-1s, it is abundantly clear that these agents will not become universally available

Nature 507 , 109113 (2014)